Studies
Every protocol under management. Open a study for its twelve-step lifecycle checklist, documents and agent reasoning trail.
List 19
| Study | Phase | Indication | Therapy | Sponsor | Category | Status | |
|---|---|---|---|---|---|---|---|
| A Phase III, Randomized, Do… A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Vers… | III | Non-Small Cell Lung Cancer | Torivumab (programmed death receptor-1 blocking antibody) + platinum-based chemotherapy | Simulated Sponsor (synthetic data) | simulated | active | Open |
| A Phase 1 Study to Evaluate… A Phase 1 Study to Evaluate Intratumoral Doxorubicin Exposure Following Adminis… | I | Soft-tissue sarcoma | Aldoxorubicin 350 mg/m² vs doxorubicin 75 mg/m² (single dose, intratumoral PK bridging) | Gemini Therapeutics (IND 113695) | simulated | startup | Open |
| A Multicenter, Randomized, … A Multicenter, Randomized, Open-Label Phase 2b Study to Investigate the Prelimi… | II | Soft-tissue sarcoma | Aldoxorubicin (INNO-206, doxorubicin-EMCH) 350 mg/m² IV (260 mg/m² doxorubicin equivalent) vs doxorubicin 75 mg/m² IV, Day 1 every 21 days for up to 6 cycles, first-line | CytRx Corporation (registry sponsor now ImmunityBio, Inc.) | simulated | completed | Open |
| APROMISS: catequentinib (AL… APROMISS: catequentinib (AL3818) in ASPS, leiomyosarcoma and synovial sarcoma | III | Alveolar soft part sarcoma, leiomyosarcoma, synovial sarcoma | Catequentinib (AL3818), oral multi-kinase TKI (VEGFR1-3, FGFR1-4, PDGFR, c-Kit, RET) | Advenchen Laboratories | staged | recruiting | Open |
| Catequentinib alone or with… Catequentinib alone or with AL58805, temozolomide or CCNU (incl. STS cohorts) | Ib/IIa | Soft tissue sarcoma, endometrial cancer, low-grade serous ovarian cancer, glioblastoma | Catequentinib (AL3818) TKI, with AL58805 (PI3K/mTOR inhibitor) in STS cohorts A2/D | Advenchen Laboratories | staged | not_yet_recruiting | Open |
| AL58805 with AL8326, eribul… AL58805 with AL8326, eribulin or fulvestrant in gynaecological cancers, STS and… | Ib/IIa | Soft tissue sarcoma, gynaecological cancers, breast cancer | AL58805, oral dual PI3K/mTOR inhibitor | Advenchen Pharmaceuticals | staged | not_yet_recruiting | Open |
| ADCElerate1: ADCE-D01 (uPAR… ADCElerate1: ADCE-D01 (uPARAP ADC) in advanced soft tissue sarcoma | I/II | Metastatic or unresectable soft tissue sarcoma | ADCE-D01, anti-uPARAP antibody-drug conjugate (topoisomerase I payload) | Adcendo ApS | staged | recruiting | Open |
| AGX101 (TM4SF1 ADC) in adva… AGX101 (TM4SF1 ADC) in advanced solid tumours incl. angiosarcoma | I | Advanced solid tumours incl. angiosarcoma | AGX101, anti-TM4SF1 antibody-drug conjugate (tubulin-inhibitor payload) | Angiex | staged | recruiting | Open |
| HH2853-G101: EZH1/2 inhibit… HH2853-G101: EZH1/2 inhibitor in r/r NHL and advanced solid tumours incl. epith… | I/II | Epithelioid sarcoma; relapsed/refractory non-Hodgkin lymphoma | HH2853, oral EZH1/EZH2 dual inhibitor | Haihe Biopharma | staged | recruiting | Open |
| QB46C-H07: intratumoural ti… QB46C-H07: intratumoural tigilanol tiglate in advanced soft tissue sarcoma | IIa | Soft tissue sarcoma of the extremities and body wall | Tigilanol tiglate, intratumoural PKC activator | QBiotics Group | staged | recruiting | Open |
| ATLAS: [225Ac]RTX-2358 (FAP… ATLAS: [225Ac]RTX-2358 (FAP radioligand) in relapsed or refractory soft tissue … | I/II | Relapsed or refractory soft tissue sarcoma | [225Ac]RTX-2358, actinium-225 radioligand against FAP | Ratio Therapeutics | staged | recruiting | Open |
| ST-01156 ST-01156-101: RBM39 molecular glue degrader in advanced solid tumours incl. Ewi… | I/Ib | Advanced solid tumours incl. Ewing sarcoma | ST-01156, oral RBM39 molecular glue degrader | SEED Therapeutics | staged | recruiting | Open |
| Luca-1: SHY-ONC6 (19S prote… Luca-1: SHY-ONC6 (19S proteasome ATPase inhibitor) in advanced solid tumours | Ia/Ib | Advanced solid tumours (10 types) incl. soft tissue sarcoma | SHY-ONC6, oral non-covalent 19S proteasome AAA+ ATPase inhibitor | SHY Therapeutics | staged | recruiting | Open |
| ADCLARA-01 ADCLARA-01: SOT106 (LRRC15 ADC) in LRRC15-positive osteosarcoma and STS | I/II | LRRC15-positive osteosarcoma and soft tissue sarcoma | SOT106, anti-LRRC15 antibody-drug conjugate (MMAE payload) | SOTIO Biotech | staged | not_yet_recruiting | Open |
| STC-15 STC-15 (METTL3 inhibitor) with toripalimab, and as monotherapy in selected sarc… | Ib/II | Dedifferentiated liposarcoma, uterine and non-uterine leiomyosarcoma; other advanced cancers | STC-15, oral METTL3 (m6A RNA methyltransferase) inhibitor | STORM Therapeutics | staged | recruiting | Open |
| Afamitresgene autoleucel (M… Afamitresgene autoleucel (MAGE-A4 TCR-T) Phase 1 dose escalation | I | MAGE-A4-positive solid tumours incl. synovial sarcoma and MRCLS | Afamitresgene autoleucel (afami-cel, Tecelra), autologous MAGE-A4 TCR-T (HLA-A*02) | US WorldMeds (ex-Adaptimmune) | staged | active_not_recruiting | Open |
| SPEARHEAD-1 SPEARHEAD-1: afamitresgene autoleucel in advanced synovial sarcoma and MRCLS | II | Advanced synovial sarcoma, myxoid/round cell liposarcoma | Afamitresgene autoleucel (afami-cel, Tecelra), autologous MAGE-A4 TCR-T | US WorldMeds (ex-Adaptimmune) | staged | active_not_recruiting | Open |
| SPEARHEAD-3 SPEARHEAD-3: afamitresgene autoleucel paediatric basket | I/II | MAGE-A4-positive synovial sarcoma, MPNST, neuroblastoma, osteosarcoma (ages 2-17) | Afamitresgene autoleucel (afami-cel, Tecelra), autologous MAGE-A4 TCR-T | US WorldMeds (ex-Adaptimmune) | staged | recruiting | Open |
| ZL-6201 ZL-6201-001: LRRC15 ADC in sarcoma and selected epithelial solid tumours | Ia/Ib | Sarcoma and selected epithelial solid tumours | ZL-6201, anti-LRRC15 antibody-drug conjugate (topoisomerase I payload, DAR 8) | Zai Lab | staged | recruiting | Open |
New study
Created as a draft; feasibility runs on the first pipeline pass.